Entity
  • SeaBeLife Biotech

    Created in 2019
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,754
  • Activities

  • Technologies

  • Entity types

  • Location

    Pl. Georges Teissier, 29680 Roscoff, France

    Roscoff

    France

  • Employees

    Scale: 2-10

    Estimated: 15

  • Engaged corporates

    18
    4 15
  • Added in Motherbase

    1 year, 11 months ago
Description
  • Value proposition

    Solutions to deprogram cell death : A breakthrough innovation to treat and prevent severe pathologies


    We develop small molecules that inhibit regulated necrosis using an original mechanism of action. Regulated necrosis is one of the recently identified pathophysiological factors in many diseases with severe outcomes. The technical, therapeutic and economic potential is major. Our activity focuses on the development of drugs inhibiting regulated necrosis, from the selection of the molecule to the proof of efficacy in the patient. We focus on acute and orphan diseases because preclinical and clinical development is facilitated, allowing proof of concept (POC) to be provided in humans more quickly. We have selected a lead molecule which is currently under preclinical development to treat acute kidney injury (AKI) induced by anti-cancer treatments (such as cisplatin) and to treat acute liver failure (ALF) induced by paracetamol poisoning. We have already identified molecules in our pipeline for which we obtained in cellulo POC in Neurodegenerative diseases and AMD.

    Nécrose régulée, Insuffisance rénale aiguë, Insuffisance hépatique aiguë, Ferroptose, Nécroptose, Intoxication médicamenteuse, néphrotoxicité, hépatotoxicité, maladies neurodégénératives, Paracetamol, and Cisplatine

  • Original language

    Une innovation de rupture pour combattre la mort cellulaire

    SeaBeLife développe des molécules innovantes pour traiter des pathologies sévères impliquant la nécrose régulée. Nos molécules brevetées s'attaquent à la mort cellulaire selon un mécanisme d'action original. Le potentiel thérapeutique et économique est majeur, la nécrose régulée joue un rôle clé dans la pathogenèse de maladies graves: insuffisances hépatique ou rénale aiguë, ischémies cardiaque et cérébrale, maladies neurodégénératives et DMLA.

Corporate interactions BETA
Corporate TypeTweets Articles
Gouvernement Gouvernement
Other

3 Oct 2024


Ministère de la Santé Ministère de la Santé
Other

3 Oct 2024


Ministère de l'Enseignement supérieur et de la Recherche Ministère de l'Enseignement supérieur et de la Recherche
Government Administration
Other

3 Oct 2024


EY
EY
Consulting, audit, IT Services and IT Consulting
EY
Consulting, audit, IT Services and IT Consulting
Other

4 Jun 2024


Viva Technology
Viva Technology
Trade show, IT Services and IT Consulting
Viva Technology
Trade show, IT Services and IT Consulting
Other

5 Apr 2024


Groupe Crédit Agricole Groupe Crédit Agricole
Bank, Banking
Other

24 Mar 2024


La French Tech Brest Bretagne Ouest
La French Tech Brest Bretagne Ouest
French Tech, Government Relations Services
La French Tech Brest Bretagne Ouest
French Tech, Government Relations Services
Other

2 Dec 2023


WeLike
WeLike
Startup accelerator & VC, Venture Capital and Private Equity Principals
WeLike
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

26 Sep 2023


CNRS Innovation
CNRS Innovation
Research, Research Services
CNRS Innovation
Research, Research Services
Other

19 Jan 2024


Eurostat
Eurostat
European Union, Environmental Services
Eurostat
European Union, Environmental Services
Other

5 May 2023


Similar entities
Loading...
Loading...
Social network dynamics